Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): Potential targeted therapy in patients with poor risk CD20+ BL and pre-B-ALL

British Journal of Haematology

Volumn 171, Issue 5, 2015, Pages 763-775

  Awasthi, Aradhana ^a   Ayello, Janet ^a   Van de Ven, Carmella ^a   Elmacken, Mona ^a   Sabulski, Anthony ^a   Barth, Matthew J ^b   Czuczman, Myron S ^b   Islam, Humayun ^a   Klein, Christian ^c   Cairo, Mitchell S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Roche Pharmaceutical Research and Early Development   (Switzerland)

Author keywords

Obinutuzumab; Pre B ALL; Rituximab; Rituximab resistant BL; Rituximab sensitive BL

Indexed keywords

CD20 ANTIGEN; OBINUTUZUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; CASPASE; GAMMA INTERFERON; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; BURKITT LYMPHOMA CELL LINE; CANCER RESISTANCE; CELL DEATH; CELL EXPANSION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; K562 CELL LINE; LEUKEMIA CELL LINE; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RAJI 4RH CELL LINE; RAJI CELL LINE; TREATMENT DURATION; TUMOR XENOGRAFT; U 698 M CELL LINE; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL PROLIFERATION; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MOLECULARLY TARGETED THERAPY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; SURVIVAL ANALYSIS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BURKITT LYMPHOMA; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RITUXIMAB; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84955331603     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13764     Document Type: Article

References (44)

1. Barth, M., Raetz, E. & Cairo, M.S. (2012a) The future role of monoclonal antibody therapy in childhood acute leukaemias. British Journal of Haematology, 159, 3-17.
2. Barth, M.J., Hernandez-Ilizaliturri, F.J., Mavis, C., Tsai, P.C., Gibbs, J.F., Deeb, G. & Czuczman, M.S. (2012b) Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British Journal of Haematology, 156, 490-498.
3. Barth, M.J., Goldman, S., Smith, L., Perkins, S., Shiramizu, B., Gross, T.G., Harrison, L., Sanger, W., Geyer, M.B., Giulino-Roth, L. & Cairo, M.S. (2013) Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. British Journal of Haematology, 162, 678-683.
4. Beers, S.A., French, R.R., Chan, H.T., Lim, S.H., Jarrett, T.C., Vidal, R.M., Wijayaweera, S.S., Dixon, S.V., Kim, H., Cox, K.L., Kerr, J.P., Johnston, D.A., Johnson, P.W., Verbeek, J.S., Glennie, M.J. & Cragg, M.S. (2010) Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood, 115, 5191-5201.
5. Bologna, L., Gotti, E., Manganini, M., Rambaldi, A., Intermesoli, T., Introna, M. & Golay, J. (2011) Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. The Journal of Immunology, 186, 3762-3769.
6. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754-758.
7. Cheson, B.D. & Leonard, J.P. (2008) Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. New England Journal of Medicine, 359, 613-626.
8. Chu, Y., Hochberg, J., Yahr, A., Ayello, J., van de Ven, C., Barth, M., Czuczman, M. & Cairo, M.S. (2015) Targeting CD20+ aggressive B-cell non-hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunology Research, 3, 333-344.
9. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
10. Czuczman, M.S., Olejniczak, S., Gowda, A., Kotowski, A., Binder, A., Kaur, H., Knight, J., Starostik, P., Deans, J. & Hernandez-Ilizaliturri, F.J. (2008) Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clinical Cancer Research, 14, 1561-1570.
11. Dalle, S., Reslan, L., Besseyre de Horts, T., Herveau, S., Herting, F., Plesa, A., Friess, T., Umana, P., Klein, C. & Dumontet, C. (2011) Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Molecular Cancer Therapeutics, 10, 178-185.
12. Davis, T.A., Czerwinski, D.K. & Levy, R. (1999) Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clinical Cancer Research, 5, 611-615.
13. Day, C.P., Carter, J., Bonomi, C., Esposito, D., Crise, B., Ortiz-Conde, B., Hollingshead, M. & Merlino, G. (2009) Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study. Pigment Cell and Melanoma Research, 22, 283-295.
14. Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W.H. & Campana, D. (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Research, 69, 4010-4017.
15. Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C.M., Chagorova, T., de la Serna, J., Dilhuydy, M.S., Illmer, T., Opat, S., Owen, C.J., Samoylova, O., Kreuzer, K.A., Stilgenbauer, S., Dohner, H., Langerak, A.W., Ritgen, M., Kneba, M., Asikanius, E., Humphrey, K., Wenger, M. & Hallek, M. (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. New England Journal of Medicine, 370, 1101-1110.
16. Golay, J., Da Roit, F., Bologna, L., Ferrara, C., Leusen, J.H., Rambaldi, A., Klein, C. & Introna, M. (2013) Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood, 122, 3482-3491.
17. Goldman, S., Smith, L., Anderson, J.R., Perkins, S., Harrison, L., Geyer, M.B., Gross, T.G., Weinstein, H., Bergeron, S., Shiramizu, B., Sanger, W., Barth, M., Zhi, J. & Cairo, M.S. (2013) Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia, 27, 1174-1177.
18. Goldman, S., Smith, L., Galardy, P., Perkins, S.L., Frazer, J.K., Sanger, W., Anderson, J.R., Gross, T.G., Weinstein, H., Harrison, L., Shiramizu, B., Barth, M. & Cairo, M.S. (2014) Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. British Journal of Haematology, 167, 394-401.
19. Heinrich, D.A., Weinkauf, M., Hutter, G., Zimmermann, Y., Jurinovic, V., Hiddemann, W. & Dreyling, M. (2015) Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma. British Journal of Haematology, 168, 606-610.
20. Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., Duong, M.N., Reslan, L., Gerdes, C.A., Friess, T., Baer, U., Burtscher, H., Weidner, M., Dumontet, C., Umana, P., Niederfellner, G., Bacac, M. & Klein, C. (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Molecular Cancer Therapeutics, 12, 2031-2042.
21. Herting, F., Friess, T., Bader, S., Muth, G., Holzlwimmer, G., Rieder, N., Umana, P. & Klein, C. (2014) Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leukaemia & Lymphoma, 55, 2151-5160.
22. Jeha, S., Behm, F., Pei, D., Sandlund, J.T., Ribeiro, R.C., Razzouk, B.I., Rubnitz, J.E., Hijiya, N., Howard, S.C., Cheng, C. & Pui, C.H. (2006) Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood, 108, 3302-3304.
23. Laprevotte, E., Ysebaert, L., Klein, C., Valleron, W., Blanc, A., Gross, E., Laurent, G., Fournie, J.J. & Quillet-Mary, A. (2013) Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. Leukemia Research, 37, 440-446.
24. Lim, S.H., Beers, S.A., French, R.R., Johnson, P.W., Glennie, M.J. & Cragg, M.S. (2010) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica, 95, 135-143.
25. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 1417-1423.
26. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.
27. Morschhauser, F., Leonard, J.P., Fayad, L., Coiffier, B., Petillon, M.O., Coleman, M., Schuster, S.J., Dyer, M.J., Horne, H., Teoh, N., Wegener, W.A. & Goldenberg, D.M. (2009) Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. Journal of Clinical Oncology, 27, 3346-3353.
28. Morschhauser, F., Marlton, P., Vitolo, U., Linden, O., Seymour, J.F., Crump, M., Coiffier, B., Foa, R., Wassner, E., Burger, H.U., Brennan, B. & Mendila, M. (2010a) Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Annals of Oncology, 21, 1870-1876.
29. Morschhauser, F., Mounier, N., Sebban, C., Brice, P., Solal-Celigny, P., Tilly, H., Feugier, P., Ferme, C., Copin, M.C. & Lamy, T. (2010b) Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucemies et Autres Maladies du Sang (GOELAMS). Cancer, 116, 4299-4308.
30. Mossner, E., Brunker, P., Moser, S., Puntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., Ferrara, C., Sondermann, P., Jager, C., Strein, P., Fertig, G., Friess, T., Schull, C., Bauer, S., Dal Porto, J., Del Nagro, C., Dabbagh, K., Dyer, M.J., Poppema, S., Klein, C. & Umana, P. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood, 115, 4393-4402.
31. Niederfellner, G., Lammens, A., Mundigl, O., Georges, G.J., Schaefer, W., Schwaiger, M., Franke, A., Wiechmann, K., Jenewein, S., Slootstra, J.W., Timmerman, P., Brannstrom, A., Lindstrom, F., Mossner, E., Umana, P., Hopfner, K.P. & Klein, C. (2011) Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood, 118, 358-367.
32. Nishimura, R., Baker, J., Beilhack, A., Zeiser, R., Olson, J.A., Sega, E.I., Karimi, M. & Negrin, R.S. (2008) In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood, 112, 2563-2574.
33. Perkins, S.L., Lones, M.A., Davenport, V. & Cairo, M.S. (2003) B-Cell non-Hodgkin's lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children's cancer group report. Clinical Advances in Hematology and Oncology, 1, 314-317.
34. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology, 7, 379-391.
35. Pievani, A., Belussi, C., Klein, C., Rambaldi, A., Golay, J. & Introna, M. (2011) Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood, 117, 510-518.
36. Radford, J., Davies, A., Cartron, G., Morschhauser, F., Salles, G., Marcus, R., Wenger, M., Lei, G., Wassner-Fritsch, E. & Vitolo, U. (2013) Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood, 122, 1137-1143.
37. Salles, G., Morschhauser, F., Lamy, T., Milpied, N., Thieblemont, C., Tilly, H., Bieska, G., Asikanius, E., Carlile, D., Birkett, J., Pisa, P. & Cartron, G. (2012) Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood, 119, 5126-5132.
38. Salles, G.A., Morschhauser, F., Solal-Celigny, P., Thieblemont, C., Lamy, T., Tilly, H., Gyan, E., Lei, G., Wenger, M., Wassner-Fritsch, E. & Cartron, G. (2013) Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. Journal of Clinical Oncology, 31, 2920-2926.
39. Small, S. (2013) Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia. Clinical Advances in Hematology and Oncology, 11, 809-810.
40. Terszowski, G., Klein, C. & Stern, M. (2014) KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. The Journal of Immunology, 192, 5618-5624.
41. Tiwari, A.A., Ayello, J., Van de Ven, C. & Mitchell, C.S. (2012) Obinutuzumab (GA101): a novel type II glycoengineered CD20 antibody exhibits enhanced cell death against Rituximab-resistant and sensitive cell lines in B-cell non-Hodgkin lymphoma. Cancer Research, 72, 516.
42. Tsai, P.C., Hernandez-Ilizaliturri, F.J., Bangia, N., Olejniczak, S.H. & Czuczman, M.S. (2012) Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clinical Cancer Research, 18, 1039-1050.
43. Ujjani, C. & Cheson, B.D. (2013) The current status and future impact of targeted therapies in non-Hodgkin lymphoma. Expert Review of Hematology, 6, 191-202. quiz 203.
44. Wierda, W.G., Johnson, M.M., Do, K.A., Manshouri, T., Dey, A., O'Brien, S., Giles, F.J., Kantarjian, H., Thomas, D., Faderl, S., Lerner, S., Keating, M. & Albitar, M. (2003) Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. British Journal of Haematology, 120, 452-456.